MACE | ||
---|---|---|
Potential Predictors | HR (95% CI) | p value |
Baseline | ||
Age (year) | 1.03 (1.01–1.04) | < 0.001 |
Female sex | 1.60 (1.07–2.38) | 0.021 |
Body mass index (kg/m2) | 1.05 (1.02–1.08) | 0.001 |
Referral reasons | ||
Acute (< 2 weeks) vs. subacute presentation (≥2 weeks) | 1.87 (1.22–2.86) | 0.003 |
History | ||
Hypertension | 1.72 (1.14–2.61) | 0.011 |
Tobacco | 1.59 (0.99–2.58) | 0.057 |
Diabetes | 2.51 (1.49–4.22) | 0.001 |
Dyslipidemia | 1.46 (0.93–2.28) | 0.101 |
Medications | ||
Aspirin | 1.47 (1.19–1.82) | < 0.001 |
ACE inhibitors | 1.80 (1.21–2.68) | 0.004 |
Beta-blockers | 2.34 (1.55–3.51) | < 0.001 |
Diuretics | 3.03 (2.01–4.56) | < 0.001 |
Statins | 1.50 (0.95–2.35) | 0.080 |
Insulin | 3.62 (1.82–7.21) | < 0.001 |
ECG | ||
Abnormal ECG | 1.16 (0.78–1.74) | 0.455 |
Laboratory Testing’s | ||
Troponin abnormal | 1.01 (0.57–1.79) | 0.968 |
Creatine-kinase abnormal | 1.19 (0.62–2.29) | 0.596 |
White blood cell count abnormal | 1.79 (1.09–2.92) | 0.021 |
CMR characteristics | ||
LVEF (%) | 0.95 (0.94–0.97) | < 0.001 |
LVEDVi (ml/m2) | 1.01 (1.00–1.02) | < 0.001 |
LVESVi (ml/m2) | 1.01 (1.01–1.02) | < 0.001 |
LV mass index (g/m2) | 1.01 (1.00–1.03) | 0.021 |
RVEF (%) | 0.95 (0.93–0.96) | < 0.001 |
RVEDVi (ml/m2) | 1.00 (0.99–1.01) | 0.570 |
RVESVi (ml/m2) | 1.02 (1.01–1.03) | < 0.001 |
Pericardial effusion | 2.31 (1.54–3.45) | < 0.001 |
T2- weighted imaging (SIR ≥2) | 2.14 (1.30–3.52) | 0.003 |
CMR LGE quantifications methods | ||
LGE mass (g) | ||
- 2-SD | 1.02 (1.00–1.03) | 0.011 |
- 3-SD | 1.02 (0.99–1.04) | 0.064 |
- 4-SD | 1.02 (0.99–1.05) | 0.162 |
- 5-SD | 1.01 (0.97–1.06) | 0.356 |
- 6-SD | 1.01 (0.95–1.07) | 0.754 |
- 7-SD | 1.00 (0.92–1.09) | 0.973 |
- FWHM | 1.04 (1.02–1.06) | 0.001 |
CMR LGE visual assessment | ||
LGE presence | 2.22 (1.47–3.35) | < 0.001 |
LGE-VPS | 1.09 (1.04–1.15) | < 0.001 |
LGE-VTS | 1.02 (1.01–1.04) | < 0.001 |